EGFR expression EGFR expression	Squamous Cell Carcinoma of Head and Neck SCCHN	EGFR expression EGFR expression	Squamous Cell Carcinoma of Head and Neck SCCHN	MRG003 Sensitive: C3 – Early Trials JAMA Oncol - 3 weeks (NewC3)	MRG003 Sensitive: C3 – Early Trials JAMA Oncol - 3 weeks - (New C3)
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	nivolumab Sensitive: A1 - Approval	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	TPF Sensitive: A1 - Approval	TPF Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: A1 - Approval	cetuximab Sensitive: A1 - Approval
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	methotrexate Sensitive: A2 - Guideline	methotrexate Sensitive: A2 - Guideline
PD-L1 negative PD-L1 negative	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 negative PD-L1 negative	Squamous Cell Carcinoma of Head and Neck SCCHN	methotrexate Sensitive: A2 - Guideline	methotrexate Sensitive: A2 - Guideline
PD-L1 negative PD-L1 negative	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 negative PD-L1 negative	Squamous Cell Carcinoma of Head and Neck SCCHN	TPeX Sensitive: A2 - Guideline	TPeX Sensitive: A2 - Guideline
PD-L1 negative PD-L1 negative	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 negative PD-L1 negative	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
PD-L1 negative PD-L1 negative	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 negative PD-L1 negative	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: A2 - Guideline	cetuximab Sensitive: A2 - Guideline
PD-L1 negative PD-L1 negative	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 negative PD-L1 negative	Squamous Cell Carcinoma of Head and Neck SCCHN	5-fluorouracil Sensitive: A2 - Guideline	5-fluorouracil Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	ADX-2191 Sensitive: A2 - Guideline	ADX-2191 Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: A2 - Guideline	cetuximab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	5-fluorouracil Sensitive: A2 - Guideline	5-fluorouracil Sensitive: A2 - Guideline
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	TPeX Sensitive: A2 - Guideline	TPeX Sensitive: A2 - Guideline
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	cisplatin Sensitive: A2 - Guideline	cisplatin Sensitive: A2 - Guideline
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	5-fluorouracil Sensitive: A2 - Guideline	5-fluorouracil Sensitive: A2 - Guideline
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab + nivolumab Sensitive: A2 - Guideline	pembrolizumab + nivolumab Sensitive: A2 - Guideline
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	carboplatin + 5-fluorouracil Sensitive: A2 - Guideline	carboplatin + 5-fluorouracil Sensitive: A2 - Guideline
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	AT-406 Sensitive: B - Late Trials	AT-406 Sensitive: B - Late Trials
CDKN2A negative CDKN2A negative	Squamous Cell Carcinoma of Head and Neck SCCHN	CDKN2A negative CDKN2A negative	Squamous Cell Carcinoma of Head and Neck SCCHN	panitumumab Sensitive: B - Late Trials	panitumumab Sensitive: B - Late Trials
HRAS mutation HRAS mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	HRAS mutation HRAS mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	tipifarnib Sensitive: B - Late Trials	tipifarnib Sensitive: B - Late Trials
TMB-H TMB-H	Squamous Cell Carcinoma of Head and Neck SCCHN	TMB-H TMB-H	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab Sensitive: B - Late Trials	durvalumab Sensitive: B - Late Trials
TMB-H TMB-H	Squamous Cell Carcinoma of Head and Neck SCCHN	TMB-H TMB-H	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: B - Late Trials	pembrolizumab Sensitive: B - Late Trials
TMB-H TMB-H	Squamous Cell Carcinoma of Head and Neck SCCHN	TMB-H TMB-H	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab + CP-675206 Sensitive: B - Late Trials	durvalumab + CP-675206 Sensitive: B - Late Trials
KMT2D mutation KMT2D mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	KMT2D mutation KMT2D mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab + CP-675206 Sensitive: B - Late Trials	durvalumab + CP-675206 Sensitive: B - Late Trials
EGFR amplification EGFR amplification	Squamous Cell Carcinoma of Head and Neck SCCHN	EGFR amplification EGFR amplification	Squamous Cell Carcinoma of Head and Neck SCCHN	afatinib Sensitive: B - Late Trials	afatinib Sensitive: B - Late Trials
ERBB3-L ERBB3-L	Squamous Cell Carcinoma of Head and Neck SCCHN	ERBB3-L ERBB3-L	Squamous Cell Carcinoma of Head and Neck SCCHN	afatinib Sensitive: B - Late Trials	afatinib Sensitive: B - Late Trials
CDKN2A negative CDKN2A negative	Squamous Cell Carcinoma of Head and Neck SCCHN	CDKN2A negative CDKN2A negative	Squamous Cell Carcinoma of Head and Neck SCCHN	afatinib Sensitive: B - Late Trials	afatinib Sensitive: B - Late Trials
PTEN-H PTEN-H	Squamous Cell Carcinoma of Head and Neck SCCHN	PTEN-H PTEN-H	Squamous Cell Carcinoma of Head and Neck SCCHN	afatinib Sensitive: B - Late Trials	afatinib Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab Sensitive: B - Late Trials	durvalumab Sensitive: B - Late Trials
ATM mutation ATM mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	ATM mutation ATM mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab + CP-675206 Sensitive: B - Late Trials	durvalumab + CP-675206 Sensitive: B - Late Trials
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	eftilagimod alpha Sensitive: B - Late Trials	eftilagimod alpha Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	nivolumab + ipilimumab Sensitive: B - Late Trials	nivolumab + ipilimumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab Sensitive: C1 - Off-label	durvalumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	nivolumab Sensitive: C1 - Off-label	nivolumab Sensitive: C1 - Off-label
EGFR expression EGFR expression	Squamous Cell Carcinoma of Head and Neck SCCHN	EGFR expression EGFR expression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: C1 - Off-label	cetuximab Sensitive: C1 - Off-label
EGFR overexpression EGFR overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	EGFR overexpression EGFR overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: C2 – Inclusion Criteria	cetuximab Sensitive: C2 – Inclusion Criteria
TP53 mutation TP53 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	TP53 mutation TP53 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	AZD1775 Sensitive: C2 – Inclusion Criteria	AZD1775 Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: C2 – Inclusion Criteria	pembrolizumab Sensitive: C2 – Inclusion Criteria
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	alpelisib Sensitive: C2 – Inclusion Criteria	alpelisib Sensitive: C2 – Inclusion Criteria
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab + CP-675206 Sensitive: C2 – Inclusion Criteria	durvalumab + CP-675206 Sensitive: C2 – Inclusion Criteria
EGFR amplification EGFR amplification	Squamous Cell Carcinoma of Head and Neck SCCHN	EGFR amplification EGFR amplification	Squamous Cell Carcinoma of Head and Neck SCCHN	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
PRSS3 underexpression PRSS3 underexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	PRSS3 underexpression PRSS3 underexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: C3 – Early Trials	cetuximab Sensitive: C3 – Early Trials
TET1 mutation TET1 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	TET1 mutation TET1 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab + eftilagimod alpha Sensitive: C3 – Early Trials	pembrolizumab + eftilagimod alpha Sensitive: C3 – Early Trials
EGFRvIII mutation EGFRvIII mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	EGFRvIII mutation EGFRvIII mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Resistant: C3 – Early Trials	cetuximab Resistant: C3 – Early Trials
AREG overexpression AREG overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	AREG overexpression AREG overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Resistant: C3 – Early Trials	cetuximab Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	temsirolimus Sensitive: C3 – Early Trials	temsirolimus Sensitive: C3 – Early Trials
EGFR mutation EGFR mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	EGFR mutation EGFR mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab + ISU104 Sensitive: C3 – Early Trials	cetuximab + ISU104 Sensitive: C3 – Early Trials
NRG1 mutation NRG1 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	NRG1 mutation NRG1 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab + ISU104 Sensitive: C3 – Early Trials	cetuximab + ISU104 Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	HER-2 mutation HER-2 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab + ISU104 Sensitive: C3 – Early Trials	cetuximab + ISU104 Sensitive: C3 – Early Trials
MET positive MET positive	Squamous Cell Carcinoma of Head and Neck SCCHN	MET positive MET positive	Squamous Cell Carcinoma of Head and Neck SCCHN	nivolumab Resistant: C3 – Early Trials	nivolumab Resistant: C3 – Early Trials
TP53 mutation TP53 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	TP53 mutation TP53 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
TMB-H TMB-H	Squamous Cell Carcinoma of Head and Neck SCCHN	TMB-H TMB-H	Squamous Cell Carcinoma of Head and Neck SCCHN	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 underexpression PD-L1 underexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab sarotalocan Sensitive: C3 – Early Trials	cetuximab sarotalocan Sensitive: C3 – Early Trials
EGFR R521K EGFR R521K	Squamous Cell Carcinoma of Head and Neck SCCHN	EGFR R521K EGFR R521K	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Resistant: C3 – Early Trials	cetuximab Resistant: C3 – Early Trials
DDR2 overexpression DDR2 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	DDR2 overexpression DDR2 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	dasatinib Sensitive: C3 – Early Trials	dasatinib Sensitive: C3 – Early Trials
ERBB3 mutation ERBB3 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	ERBB3 mutation ERBB3 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab + ISU104 Sensitive: C3 – Early Trials	cetuximab + ISU104 Sensitive: C3 – Early Trials
SMARCA4 mutation + MSI-L/dMMR SMARCA4 mutation + MSI-L/dMMR	Squamous Cell Carcinoma of Head and Neck SCCHN	SMARCA4 mutation + MSI-L/dMMR SMARCA4 mutation + MSI-L/dMMR	Squamous Cell Carcinoma of Head and Neck SCCHN	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
ROS1 mutation + MSI-L/dMMR ROS1 mutation + MSI-L/dMMR	Squamous Cell Carcinoma of Head and Neck SCCHN	ROS1 mutation + MSI-L/dMMR ROS1 mutation + MSI-L/dMMR	Squamous Cell Carcinoma of Head and Neck SCCHN	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
PD-L2 overexpression PD-L2 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L2 overexpression PD-L2 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
Choline elevation Choline elevation	Squamous Cell Carcinoma of Head and Neck SCCHN	Choline elevation Choline elevation	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
IFNG RNA sig IFNG RNA sig	Squamous Cell Carcinoma of Head and Neck SCCHN	IFNG RNA sig IFNG RNA sig	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab + GSK3359609 Sensitive: C3 – Early Trials	pembrolizumab + GSK3359609 Sensitive: C3 – Early Trials
IL1A elevation IL1A elevation	Squamous Cell Carcinoma of Head and Neck SCCHN	IL1A elevation IL1A elevation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: C3 – Early Trials	cetuximab Sensitive: C3 – Early Trials
FGFR overexpression FGFR overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	FGFR overexpression FGFR overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	BAY 1163877 Sensitive: C3 – Early Trials	BAY 1163877 Sensitive: C3 – Early Trials
CXCL8 expression CXCL8 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	CXCL8 expression CXCL8 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Resistant: C3 – Early Trials	pembrolizumab Resistant: C3 – Early Trials
MET N375S MET N375S	Squamous Cell Carcinoma of Head and Neck SCCHN	MET N375S MET N375S	Squamous Cell Carcinoma of Head and Neck SCCHN	afatinib Sensitive: C3 – Early Trials	afatinib Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Resistant: C3 – Early Trials	cetuximab Resistant: C3 – Early Trials
PTEN expression PTEN expression	Squamous Cell Carcinoma of Head and Neck SCCHN	PTEN expression PTEN expression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Resistant: C3 – Early Trials	cetuximab Resistant: C3 – Early Trials
KRAS mutation KRAS mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	KRAS mutation KRAS mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Resistant: C3 – Early Trials	cetuximab Resistant: C3 – Early Trials
HRAS mutation HRAS mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	HRAS mutation HRAS mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Resistant: C3 – Early Trials	cetuximab Resistant: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	olaparib Resistant: C3 – Early Trials	olaparib Resistant: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab + CP-675206 Sensitive: C3 – Early Trials	durvalumab + CP-675206 Sensitive: C3 – Early Trials
ATM mutation ATM mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	ATM mutation ATM mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab Sensitive: C3 – Early Trials	durvalumab Sensitive: C3 – Early Trials
AREG expression AREG expression	Squamous Cell Carcinoma of Head and Neck SCCHN	AREG expression AREG expression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: C3 – Early Trials	cetuximab Sensitive: C3 – Early Trials
SMAD4 expression SMAD4 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	SMAD4 expression SMAD4 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: C3 – Early Trials	cetuximab Sensitive: C3 – Early Trials
TLR4 overexpression TLR4 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	TLR4 overexpression TLR4 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Resistant: C3 – Early Trials	cetuximab Resistant: C3 – Early Trials
PIK3CA E542K PIK3CA E542K	Squamous Cell Carcinoma of Head and Neck SCCHN	PIK3CA E542K PIK3CA E542K	Squamous Cell Carcinoma of Head and Neck SCCHN	GDC-0980 Sensitive: C3 – Early Trials	GDC-0980 Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab + alpelisib Sensitive: C3 – Early Trials	cetuximab + alpelisib Sensitive: C3 – Early Trials
FANCI mutation + FLT1 mutation FANCI mutation + FLT1 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	FANCI mutation + FLT1 mutation FANCI mutation + FLT1 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	AN2025 Sensitive: C3 – Early Trials	AN2025 Sensitive: C3 – Early Trials
FANCA mutation + FGFR3 mutation FANCA mutation + FGFR3 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	FANCA mutation + FGFR3 mutation FANCA mutation + FGFR3 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	AN2025 Sensitive: C3 – Early Trials	AN2025 Sensitive: C3 – Early Trials
FANCD2 mutation + EP300 mutation FANCD2 mutation + EP300 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	FANCD2 mutation + EP300 mutation FANCD2 mutation + EP300 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	AN2025 Sensitive: C3 – Early Trials	AN2025 Sensitive: C3 – Early Trials
PIK3CA mutation + EP300 mutation PIK3CA mutation + EP300 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	PIK3CA mutation + EP300 mutation PIK3CA mutation + EP300 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	AN2025 Sensitive: C3 – Early Trials	AN2025 Sensitive: C3 – Early Trials
IFNG overexpression IFNG overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	IFNG overexpression IFNG overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
IDO1 overexpression IDO1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	IDO1 overexpression IDO1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
IFI35 overexpression IFI35 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	IFI35 overexpression IFI35 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
OASL overexpression OASL overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	OASL overexpression OASL overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
CXCL9 overexpression CXCL9 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	CXCL9 overexpression CXCL9 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials

Squamous Cell Carcinoma of Head and Neck

Associations(233)

Associations
(233)